Analysis and Quantitation of the β-Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody-Based Immunoassay

Authors


  • The present address of Dr. T. Henriksson is Cetus Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608, U.S.A.

Address correspondence and reprint requests to Dr. D. B. Schenk at Athena Neurosciences, Inc., 800-F Gateway Boulevard, South San Francisco, CA 94080, U.S.A.

Abstract

Abstract: One of the major clinical findings in Alzheimer's disease (AD) is the formation of deposits of β-amyloid protein in amyloid plaques, derived from the β-amyloid precursor protein (β-APP). To determine the possible use of β-APP as a diagnostic marker for AD in CSF, a monoclonal antibody-based immunoassay specific for this protein was developed. The assay does not differentiate between β-APP695 and β-APP751 forms but does preferentially recognize β-APP751 complexed with a protease. Of the two sets of CSF samples tested, one set, obtained from living patients, gave a slightly lower level of β-APP in AD and Parkinson's disease patients relative to controls, whereas the other set, composed of postmortem samples, showed no significant differences between the AD and control groups.

Ancillary